Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TSLP

TSLP

Brief Information

Name:Thymic stromal lymphopoietin
Target Synonym:Thymic stromal lymphopoietin,TSLP
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

TSP-H52Hb-Cell-based assay
 TSLP CELL

Response to human TSLP protein (Fold).
The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Human TSLP Protein, His Tag, premium grade (AcroBiosystems, Cat. No. TSP-H52Hb). The max induction fold was approximately 45.15 (Routinely tested).

TSP-H52Ha-SPR
 TSLP SPR

Captured Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 4.22 nM as determined in SPR assay (Biacore T200) (Routinely tested).

TSP-H52Hb-SPR
 TSLP SPR

Captured Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 1.81 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

TSLP

Background

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tezepelumab AMG-157; MEDI-9929 Approved Amgen Inc Tezspire United States Asthma Astrazeneca Ab 2021-12-17 Immune System Diseases; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Sinusitis; Respiratory Hypersensitivity; Asthma; Eosinophilic Esophagitis; Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Nasal Polyps; Nose Diseases; Chronic Urticaria; Anaphylaxis; Carcinoma; Granulomatosis with Polyangiitis Details
Tezepelumab AMG-157; MEDI-9929 Approved Amgen Inc Tezspire United States Asthma Astrazeneca Ab 2021-12-17 Immune System Diseases; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Sinusitis; Respiratory Hypersensitivity; Asthma; Eosinophilic Esophagitis; Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Nasal Polyps; Nose Diseases; Chronic Urticaria; Anaphylaxis; Carcinoma; Granulomatosis with Polyangiitis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ecleralimab CSJ-117; NOV-14 Phase 2 Clinical Novartis Pharma Ag Asthma; Pulmonary Disease, Chronic Obstructive Details
WIN-1001X WIN-1001X Phase 2 Clinical Whanin Pharmaceutical Co Ltd Nerve Degeneration; Parkinson Disease Details
PF-07275315 PF-07275315 Phase 2 Clinical Pfizer Inc Dermatitis, Atopic Details
Lunsekimig SAR-443765 Phase 2 Clinical Sanofi Asthma; Inflammation Details
Bosakitug BSI-045B; TQC-2731; TQC2731 Phase 2 Clinical Biosion Inc Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic Details
SHR-1905 SHR-1905; AIO-001 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Nasal Polyps; Nose Diseases; Respiratory Tract Diseases; Sinusitis; Asthma Details
CM-326(Connaught Biomedical Technology) CM-326 Phase 2 Clinical Keymed Biosciences Co Ltd Nose Diseases; Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details
PF-06342674 RN-168; PF-6342674; PF-06342674; ZB-168 Phase 1 Clinical Pfizer Inc Diabetes Mellitus, Type 1; Multiple Sclerosis Details
HBM-9378 SKB378; HBM-9378 Phase 1 Clinical Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Asthma Details
IBI-3002 IBI3002; IBI-3002 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Asthma Details
GB-0895 GB-0895 Phase 1 Clinical Generate Biomedicines Inc Immune System Diseases; Asthma Details
STSA-1201 STSA-1201; STSA1201 Phase 1 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Asthma Details
LQ043H LQ043H Phase 1 Clinical Shanghai Novamab Biopharmaceuticals Co Ltd Asthma Details
GR2002 GR2002 Phase 1 Clinical Genrix (Shanghai) Biopharmaceutical Co Ltd Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic Details
AZD-8630 AZD-8630; AMG-104 Phase 1 Clinical Astrazeneca Plc, Amgen Inc Asthma Details
QX-008N QX008N; QX-008N Phase 1 Clinical Qyuns Therapeutics Co Ltd Asthma; Pulmonary Disease, Chronic Obstructive Details
BD-9 BD-9 Biolojic Design Inc Details
Ecleralimab CSJ-117; NOV-14 Phase 2 Clinical Novartis Pharma Ag Asthma; Pulmonary Disease, Chronic Obstructive Details
WIN-1001X WIN-1001X Phase 2 Clinical Whanin Pharmaceutical Co Ltd Nerve Degeneration; Parkinson Disease Details
PF-07275315 PF-07275315 Phase 2 Clinical Pfizer Inc Dermatitis, Atopic Details
Lunsekimig SAR-443765 Phase 2 Clinical Sanofi Asthma; Inflammation Details
Bosakitug BSI-045B; TQC-2731; TQC2731 Phase 2 Clinical Biosion Inc Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic Details
SHR-1905 SHR-1905; AIO-001 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Nasal Polyps; Nose Diseases; Respiratory Tract Diseases; Sinusitis; Asthma Details
CM-326(Connaught Biomedical Technology) CM-326 Phase 2 Clinical Keymed Biosciences Co Ltd Nose Diseases; Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details
PF-06342674 RN-168; PF-6342674; PF-06342674; ZB-168 Phase 1 Clinical Pfizer Inc Diabetes Mellitus, Type 1; Multiple Sclerosis Details
HBM-9378 SKB378; HBM-9378 Phase 1 Clinical Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Asthma Details
IBI-3002 IBI3002; IBI-3002 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Asthma Details
GB-0895 GB-0895 Phase 1 Clinical Generate Biomedicines Inc Immune System Diseases; Asthma Details
STSA-1201 STSA-1201; STSA1201 Phase 1 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Asthma Details
LQ043H LQ043H Phase 1 Clinical Shanghai Novamab Biopharmaceuticals Co Ltd Asthma Details
GR2002 GR2002 Phase 1 Clinical Genrix (Shanghai) Biopharmaceutical Co Ltd Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic Details
AZD-8630 AZD-8630; AMG-104 Phase 1 Clinical Astrazeneca Plc, Amgen Inc Asthma Details
QX-008N QX008N; QX-008N Phase 1 Clinical Qyuns Therapeutics Co Ltd Asthma; Pulmonary Disease, Chronic Obstructive Details
BD-9 BD-9 Biolojic Design Inc Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message